Evidence map›Paper›PMID 27330903›Full record

ReviewSpringerPlus2016

Recent advances in migraine therapy.

Fabio Antonaci, Natascia Ghiotto, Shizheng Wu, Ennio Pucci, Alfredo Costa

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in SpringerPlus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 3 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Non-invasive neuromodulation in the acute treatment of migraine: a systematic review and meta-analysis of randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  2. Short-term efficacy and safety of lasmiditan, a novel 5-HTThe journal of headache and pain · 2020
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Calcium Ions in the Physiology and Pathology of the Central Nervous System.International journal of molecular sciences · 2024
    Review
  13. Article
  14. Article
  15. Review
  16. Design and evaluation of sustained release mucoadhesive film of sumatriptan succinate containing grafted co-polymer as the platform.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Fabio AntonaciHeadache Center, C. Mondino National Neurological Institute, Pavia, Italy ; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Natascia GhiottoHeadache Center, C. Mondino National Neurological Institute, Pavia, Italy.
Shizheng WuChina Qinghai Provincial People's Hospital, Xining, China.
Ennio PucciHeadache Center, C. Mondino National Neurological Institute, Pavia, Italy ; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Alfredo CostaHeadache Center, C. Mondino National Neurological Institute, Pavia, Italy ; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Fondazione Istituto Neurologico Nazionale Casimiro Mondino · ITQinghai Provincial Peoples Hospital · CNUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is a common and highly disabling neurological disorder associated with a high socioeconomic burden. Effective migraine management depends on adequate patient education: to avoid unrealistic expectations, the condition must be carefully explained to the patient soon as it is diagnosed. The range of available acute treatments has increased over time. At present, abortive migraine therapy can be classed as specific (ergot derivatives and triptans) or non-specific (analgesics and non-steroidal anti-inflammatory drugs). Even though acute symptomatic therapy can be optimised, migraine continues to be a chronic and potentially progressive condition. In addition to the drugs officially approved for migraine prevention by international governmental regulatory agencies, numerous different agents are commonly used for this indication, showing various levels of evidence of efficacy and tolerability. Guidelines published in recent years, based on evidence-based medicine data on migraine prophylaxis, are a useful source of guidance, especially for primary care physicians and neurologists without specific expertise in headache medicine. Although the field of pharmacological migraine prevention has seen few advances in recent years, potential novel approaches are now being developed. This review looks at emerging pharmacological strategies for acute and preventive migraine treatment that are nearing or have already entered the clinical trial phase. Specifically, it discusses preclinical and clinical data on compounds acting on calcitonin gene-related peptide or its receptor, the serotonin 5-HT1F receptor, nitric oxide synthase, and acid-sensing ion channel blockers.

Indexed as

Acute treatmentMigrainePreventive treatment

Identifiers

PMID27330903
PMCPMC4870579
OpenAlexW2399750252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.